Evidence Level
Moringa has been extensively studied since the 2010s, with over 1,300 studies published to date. The majority of these remain preclinical, though some human trials have emerged. A notable clinical trial conducted in 2016 demonstrated that 4g daily of moringa leaf powder reduced fasting glucose by 28% over a 40-day period (Taweerutchana et al., 2017). Anti-inflammatory properties are well-documented, with isothiocyanates such as moringin showing potent inhibition of the NF-κB pathway in lab settings (Waterman et al., 2015).
Cholesterol-lowering effects have been observed in small trials, though large-scale randomized controlled trials (RCTs) remain scarce. The plant's high micronutrient content underscores its potential for addressing nutritional deficiencies, particularly in vulnerable populations (Leone et al., 2015). However, key limitations include small sample sizes, short study durations, and inconsistent standardization of extracts across studies.
Recent systematic reviews and meta-analyses have provided additional insights. A 2026 review by Akiode et al. found that moringa significantly reduced ulcer index in preclinical models of peptic ulcer disease (SMD = -1.42; p < 0.01). In poultry, a 2023 meta-analysis by Ogbuewu and Mbajiorgu highlighted improvements in feed conversion ratio, egg quality, and cholesterol profiles among laying hens supplemented with moringa leaf meal. Similarly, a 2025 analysis by Sukria et al. found that moringa supplementation improved weight gain and lipid profiles in broiler chickens.
In diabetic rodent models, a 2021 systematic review by Watanabe et al. reported significant reductions in blood glucose levels (-3.92, 95% CI: -4.65 to -3.19) and improvements in lipid profiles. However, a 2025 meta-analysis of nine RCTs involving 649 participants by Crișan et al. found no significant cardiometabolic benefits from moringa supplementation, with only modest reductions in diastolic blood pressure observed.
Overall, while moringa shows promise for managing hyperglycemia and improving lipid profiles, further large-scale human trials are needed to confirm these effects and establish standardized dosages.